Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0FPQOM
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
XMT-1660
|
|||||
| Synonyms |
XMT 1660; XMT1660
Click to Show/Hide
|
|||||
| Organization |
Mersana Therapeutics, Inc.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 5 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Phase 1
Endometrial cancer [ICD11:2C76]
Phase 1
Fallopian tube cancer [ICD11:2C74]
Phase 1
Peritoneal cavity cancer [ICD11:2C51]
Phase 1
Triple negative breast cancer [ICD11:2C60-2C65]
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
6
|
|||||
| Structure |
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
V-set domain-containing T-cell activation inhibitor 1 (VTCN1)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.